A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Allergan

Status and phase: Completed; Phase 2

Conditions: Postherpetic Neuralgia

Treatments: Drug: Botulinum Toxin Type A

Study type: Interventional

Funder types: Industry

Identifiers

NCT00168441

191622-066

Details and patient eligibility

About

4-month study including a 30-day baseline phase

Enrollment: 117 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion criteria

• Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind